Clinical Trial

Phase I Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of HLX97 (a KAT6A/B Inhibitor) in Patients With Advanced/Metastatic Solid Tumor

Not Yet Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study is an open-label, multicenter Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetic profiles, and preliminary efficacy of HLX97 ( KAT6A/B inhibitor) in patients with advanced/metastatic solid tumors.
Trial Details
NCT Number NCT07480681
Lead Sponsor Shanghai Henlius Biotech
Conditions Advanced/Metastatic Solid Tumors
Enrollment 138 participants
Start Date 2026-03
Primary Completion 2028-03 (estimated)
Study Completion 2028-06 (estimated)
Updated on ClinicalTrials.gov 2026-03-18